Navigation Links
China Biologic Products Provides Preliminary Guidance for 2009 of Revenues of $90 to $100 Million and Net Income of $18 to 22 Million
Date:10/16/2008

TAIAN, Shandong, China, Oct. 16 /Xinhua-PRNewswire-FirstCall/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic" or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), issues preliminary guidance following the recently announced acquisitions which will transform the Company into the largest non-state-owned producer of plasma based products in China.

"We expect the acquisitions of a 90% controlling interest in Chongqing Dalin Biologic Technologies Co., Ltd. ("Dalin") and a 35% equity interest in Xi'an Huitian Blood Products Co., Ltd. ("Huitian") will accelerate our geographical expansion, diversify our customer base, enhance our technological capabilities or competitive advantages and serve to transform our company into the leading biopharmaceutical producer in China," said Mr. Chao Ming Zhao, CEO of China Biologic Products. "We believe the two acquisitions position China Biologic to significantly grow our revenues and profitability in 2009, while affording us the ability to increase our supply of plasma and achieve higher utilization levels over time across our expanded geographic platform."

China Biologic has targeted combined revenue for 2008 to be in the range of $48 million to $50 million and combined net income to be between $9 million to $10 million, including only a portion of the 4th quarter operations from the two acquisitions. Assuming the full year consolidation of the two acquisitions, management estimates revenues for 2009 will be in the range of $90 million to $100 million with net income between $18 million to $22 million. Management will continue to evaluate the potential synergies that may emerge from the two acquisitions.

About China Biologic Products, Inc.

Through its indirect majority-owned subsidiary Shandong Taibang Biological Products CO. Ltd., China Biologic Products, Inc. (the "Company"), is principally engaged in the research, development, production and manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. The Company's human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases.

Safe Harbor Statement

This release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the impact of the acquisitions of Chongqing Dalin Biologic Technologies Co., Ltd. and Xi'an Huitian Blood Products Co., Ltd.; the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; statements about expected future revenues and earnings; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

For more information, please contact:

Company Contact:

Mr. Chao Ming Zhao

CEO

China Biologic Products, Inc.

Tel: +86-538-6217079

Email: IR@chinabiologic.com

http://www.chinabiologic.com

Investor Relations Contact:

Mr. Crocker Coulson

President

CCG Investor Relations

Tel: +1-646-213-1915 (NY office)

Email: crocker.coulson@ccgir.com

http://www.ccgir.com


'/>"/>
SOURCE China Biologic Products, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... West Point, IA (PRWEB) , ... January 17, ... ... approval from China for Balance™ GT soybeans. The new Balance™ GT Soybean Performance ... tolerance to glyphosate and isoxaflutole, the active ingredient in the new Balance® Bean ...
(Date:1/17/2017)... , Jan. 17, 2017   Pulmatrix, Inc . ... company developing innovative inhaled therapies to address serious pulmonary ... fungal infections in the lungs of CF patients, PUR1900, ... (QIDP) by the U.S. Food & Drug Administration. ... designed to speed the development of novel drugs against ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... the North American Spine Society (NASS)1 demonstrate high fusion rates at 6 ... when PEEK-OPTIMA™ HA Enhanced is used for interbody-fusion devices. The implantable high-performance ...
(Date:1/17/2017)... , Jan. 17, 2017  Protagonist Therapeutics, ... that it has initiated a global Phase 2b ... oral peptide that targets alpha4beta7 integrin. The aim ... is to evaluate the safety/tolerability and efficacy of ... with moderate to severe active disease. ...
Breaking Biology Technology:
(Date:1/11/2017)... 2017 Intoxalock, a leading ignition interlock provider, ... its patent-pending calibration device. With this new technology, Intoxalock ... upload data logs and process repairs at service center ... "Fighting drunk driving through the application of cutting-edge technologies ... but also for the customer who can get back ...
(Date:1/6/2017)... NEWARK, Calif. , Jan. 5, 2017  Delta ... introduced its iris scanning technology for automotive at CES® ... GNTX ) to demonstrate the use of ... to identify and authenticate the driver in a car, ... automobiles during the driving experience. Delta ID ...
(Date:12/22/2016)... , Dec. 20, 2016  As part of its ... the leading personal genetics company, recently released its latest children,s ... . The book focuses on the topics of inheritance and ... Science Standards (NGSS) taught in elementary school classrooms in the ... a series by illustrator Ariana Killoran , whose previous ...
Breaking Biology News(10 mins):